Sara A. Hurvitz, MD, FACP, on Metastatic Triple-Negative Breast Cancer: More Results From ASCENT-03
ASCO 2026
Sara A. Hurvitz, MD, FACP, of Fred Hutchinson Cancer Center, provides an update focusing on progression-free survival after next line of treatment and subsequent therapies among patients enrolled in the ASCENT-03 trial. The study compared sacituzumab govitecan vs chemotherapy in patients with previously untreated metastatic triple-negative breast cancer (Abstract 1001).
The ASCO Post Staff
Asaf Maoz, MD, of Dana-Farber Cancer Institute, Mass General Brigham, and Harvard Medical School, talks about whether prospective assessment of CA 19-9 has utility as part of pancreatic cancer surveillance among high-risk individuals (Abstract 10527).
William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, presents pooled results from the BRUIN CLL-313 and BRUIN CLL-314 trials. BRUIN CLL-313 is comparing pirtobrutinib to bendamustine plus rituximab in treatment-naive patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL); BRUIN CLL-314 is comparing pirtobrutinib to ibrutinib in the same patient population (Abstract 7044).
The ASCO Post Staff
Noelle Cloven, MD, of Texas Oncology, discusses the actively recruiting RAINFOL-03 (ENGOT-EN-31/GOG-3128) study, a global, phase III, open-label, randomized study of rinatabart sesutecan vs investigator’s choice of chemotherapy in patients with endometrial cancer after receipt of platinum-based chemotherapy and PD-L1 inhibition (Abstract TPS5646).
The ASCO Post Staff
Jame Abraham, MD, FACP, of Cleveland Clinic, offers his thoughts on findings from OPTIMA (Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis), an international randomized controlled trial comparing chemotherapy decisions made with the Prosigna (PAM50) gene expression test with standard treatment in mostly node-positive patients with high clinical risk ER-positive HER2-negative early breast cancer (Abstract 500).
Daniel A. Ermann, MD, of Huntsman Cancer Institute, University of Utah School of Medicine, reviews data from a retrospective analysis that compared the real-world effectiveness of monotherapy first-line treatment for patients with chronic lymphocytic leukemia (CLL) based on overall survival and time to next treatment (Abstract 7045).
